Septerna to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Septerna (Nasdaq: SEPN) announced management will participate in two investor conferences in November 2025: a Guggenheim fireside chat on November 10, 2025 at 4:00 p.m. ET and a TD Cowen Immunology & Inflammation Summit fireside chat on November 12, 2025 at 4:00 p.m. ET.
Both presentations will be live webcast and available in the investors section at www.septerna.com. Replays will be archived for at least 30 days after each event.
Details
News Market Reaction – SEPN
On Nov 3, the day this news came out, SEPN closed 2.67% below the previous close.
Data tracked by StockTitan Argus for the Nov 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in November:
Guggenheim 2nd Annual Healthcare Innovation Conference
Fireside chat on Monday, November 10, 2025, at 4:00 p.m. ET
TD Cowen Immunology & Inflammation Summit
Fireside chat on Wednesday, November 12, 2025, at 4:00 p.m. ET
Live webcasts of the presentations will be available in the investors section of the company’s website at www.septerna.com. Replays will be archived for at least 30 days following each event.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com
Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.